{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&_metadata=all&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2015-07-14T15%3A34%3A29.197Z", "items" : [{"_about" : "http://data.parliament.uk/resources/388946", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/388946/answer", "answerText" : {"_value" : "
The Department is responsible for determining the price of medicinal products. The Department\u2019s procedures for determining price comply with the requirements of the EU Directive on the transparency of measures regulating the prices of medicinal products. The Biomarin product Vimizim (elosulfase alfa) is currently being evaluated by the National Institute for Health and Care Excellence as part of its Highly Specialised Technologies programme. In the meantime, NHS England has defined a draft commissioning policy for elosulfase alpha for Mucopolysaccharidosis IV Type A on the basis of the clinical evidence of its effectiveness. No final funding decision has been made.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T13:13:12.867Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Morquio Syndrome: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the compatibility with paragraph 9 of Article 3 of the EU directive on the transparency of measures regulating the prices of medicinal products for human use of NHS England's decision not to respond to BioMarin's pricing offer for Vimizim in October 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1540", "label" : {"_value" : "Biography information for Greg Mulholland"} } , "tablingMemberConstituency" : {"_value" : "Leeds North West"} , "tablingMemberPrinted" : [{"_value" : "Greg Mulholland"} ], "uin" : "6343"} , {"_about" : "http://data.parliament.uk/resources/388947", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/388947/answer", "answerText" : {"_value" : "
We have made no such estimate.<\/p>
<\/p>
<\/strong><\/p> <\/p> Advances in medical science mean that new cancer medicines are emerging all the time and the Cancer Drugs Fund (CDF) needs to regularly reprioritise the list so people can access these too. Decisions to add or remove drugs from the national CDF list are made by NHS England taking account of the need to ensure the resources of the Fund are used most effectively.<\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-14T13:11:07.847Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate his Department has made of the number of people likely to have been prescribed treatments in 2015-16 which has been removed from the National Cancer Drugs Fund list.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "6373"}
, {"_about" : "http://data.parliament.uk/resources/388431", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/388431/answer", "answerText" : {"_value" : " Clinical commissioning groups (CCGs) commission the majority of NHS services in England. As such, NHS England is responsible for ensuring that every CCG can access excellent affordable commissioning support services. Its principal vehicles for delivering this are through the Lead Provider Framework for commissioning support which enables CCGs to draw down a range of support services from nine high quality providers and through the oversight of NHS Commissioning Support Units, which NHS England hosts.<\/p> <\/p> <\/strong><\/p> <\/p> NHS England also has a statutory duty to produce commissioning guidance, which CCGs must have regard to, and continues to promote good commissioning through its CCG assurance framework.<\/p> <\/p> <\/p> <\/p> NHS England continues to review its support of CCGs to ensure they are well supported organisations. There are no immediate plans to change this offer.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-14T15:29:44.86Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS England"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what specific role NHS England has in supporting Clinical Commissioning Groups; and what plans, if any, they have to change this role.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/565", "label" : {"_value" : "Biography information for Lord Morris of Aberavon"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Morris of Aberavon"}
], "uin" : "HL1206"}
, {"_about" : "http://data.parliament.uk/resources/388616", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/388616/answer", "answerText" : {"_value" : " The Department is responsible for determining the price of medicinal products. The Department\u2019s procedures for determining price comply with the requirements of the EU Directive on the transparency of measures regulating the prices of medicinal products. The Biomarin product Vimizim (elosulfase alfa) is currently being evaluated by the National Institute for Health and Care Excellence as part of its Highly Specialised Technologies programme. In the meantime, NHS England has defined a draft commissioning policy for elosulfase alpha for Mucopolysaccharidosis IV Type A on the basis of the clinical evidence of its effectiveness. No final funding decision has been made.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-07-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-13T16:30:27.247Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Morquio Syndrome: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the compatibility of NHS England's announcement on 2 July 2015 on a final funding decision on Vimizim with the EU directive on transparency of measures regulating the prices of medicinal products for human use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1540", "label" : {"_value" : "Biography information for Greg Mulholland"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Greg Mulholland"}
], "uin" : "6130"}
, {"_about" : "http://data.parliament.uk/resources/388621", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/388621/answer", "answerText" : {"_value" : " NHS England advises that, of the 37 schemes selected for the second wave of Access Fund pilot schemes, one of these is based in Coventry. This scheme involves 64 general practitioner practices in the local area.<\/p> <\/p> <\/p> <\/p> In October 2013, the Prime Minister announced a new £50 million Access Fund to help improve access to general practice and stimulate innovative ways of providing primary care services. The first wave of 20 pilots was announced in April 2014.<\/p> <\/p> <\/p> <\/p> Further funding of £100 million was announced by the Prime Minister on 30 September 2014 for a second wave of schemes and an additional £25 million has since been added from the £1 billion Infrastructure Fund.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-07-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-07-13T15:02:07.043Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "General Practitioners: Coventry"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many GP practices in (a) Coventry North East constituency and (b) Coventry have received funding from the GP Access Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4378", "label" : {"_value" : "Biography information for Colleen Fletcher"}
}
, "tablingMemberConstituency" : {"_value" : "Coventry North East"}
, "tablingMemberPrinted" : [{"_value" : "Colleen Fletcher"}
], "uin" : "6057"}
, {"_about" : "http://data.parliament.uk/resources/388622", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/388622/answer", "answerText" : {"_value" : " The NHS Choices website contains lists of all mental health services and can be accessed at:<\/p> <\/p> <\/p> <\/p>